Author

J. Cassel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Assay:proteomics· 4 Research Focus:cancer & tumor microenvironment· 2 Approach:biophysical modeling· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. M. Salvino· 3 shared L. J. Montaner· 3 shared L. Lu· 2 shared A. Abbas· 1 shared A. Bar-Or· 1 shared A. Bhuniya· 1 shared A. Kossenkov· 1 shared A. M. Bowcock· 1 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

J. M. Salvino

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Targeting LxCxE cleft pocket of retinoblastoma protein in M2 macrophages inhibits ovarian cancer progression

E. N. Tcyganov, T. Kwak, X. Yang, A. N. R. Poli, C. Hart, A. Bhuniya, J. Cassel, A. Kossenkov, N. Auslander, L. Lu, P. Sharma, M. D. G. C. Mendoza, D. Zhigarev, M. G. Cadungog, S. Jean, , L. J. Montaner

This study shows targeting the LxCxE cleft pocket of Rb in M2 macrophages inhibits ovarian cancer progression by reducing immunosuppressive TAMs and enhancing T cell infiltration.

bioRxiv · May 10, 2024 · PreprintImmunology

Cloning and functional characterization of novel human neutralizing anti-interferon-alpha and anti-interferon-beta antibodies

E. Papasavvas, L. Lu, M. Fair, I. Olivia, J. Cassel, S. Majumdar, K. C. Mounzer, J. R. Kostman, P. Tebas, A. Bar-Or, K. Muthumani, L. J. Montaner

The paper isolates and characterizes neutralizing anti-interferon-alpha and anti-interferon-beta antibodies from human patients, showing their specificity and potential therapeutic applications.

bioRxiv · May 5, 2024 · PreprintImmunology

The natural stilbenoid (-)-hopeaphenol inhibits cellular entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7 and B.1.351 variants

I. Tietjen, J. Cassel, E. T. Register, X. Y. Zhou, T. E. Messick, F. Keeney, L. D. Lu, K. D. Beattie, T. Rali, H. C. Ertl, J. M. Salvino, R. A. Davis, L. J. Montaner

This paper identifies (-)-hopeaphenol and related stilbenoids as potent inhibitors of SARS-CoV-2 entry across multiple variants by blocking spike protein-ACE2 interaction.

bioRxiv · Apr 29, 2021Microbiology

SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1

A. Shepley-McTaggart, C. A. Sagum, I. Oliva, E. Rybakovsky, K. DiGuilio, J. Liang, M. T. Bedford, J. Cassel, M. Sudol, J. M. Mullin, R. N. Harty

This study identifies a specific interaction between SARS-CoV-2 E protein and PDZ-domain-2 of ZO1, suggesting a role in epithelial barrier disruption and disease severity.

bioRxiv · Dec 22, 2020Microbiology

Cancer cells are sensitive to wild-type IDH1 inhibition under nutrient limitation

A. Vaziri-Gohar, J. J. Hue, H. J. Graor, E. Prendergast, V. Chen, J. Cassel, F. S. Mohammed, A. Abbas, K. Dukleska, I. Khokhar, O. Hajhassani, M. Zarei, R. Wang, L. D. Rothermel, I. Bederman, , J. M. Winter

This study shows that wild-type IDH1 is a metabolic target in pancreatic cancer cells under nutrient limitation, and FDA-approved drugs can inhibit it effectively in preclinical models.

bioRxiv · Nov 19, 2020 · PreprintCancer Biology

Kinetics characterization of ASXL1/2-mediated allosteric regulation of BAP1 deubiquitinase

H. Peng, J. Cassel, D. McCracken, J. W. Prokop, P. R. Collop, A. Polo, S. Joshi, J. P. Mandell, K. Ayyanathan, D. Hinds, S. B. Malkowicz, J. W. Harbour, A. M. Bowcock, J. Salvino, E. J. Kennedy, , F. J. Rauscher

This study characterizes the kinetics and stoichiometry of BAP1 and ASXL2 interactions, revealing their structural and functional properties in deubiquitinase activity.

bioRxiv · Feb 24, 2020Cancer Biology